4.7 Article

Analysis of the histamine H2-receptor in human monocytes

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 92, Issue 2, Pages 369-379

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2014.08.028

Keywords

Histamine H-2-receptor; Functional selectivity; Monocyte

Ask authors/readers for more resources

Histamine receptors are G-protein-coupled receptors (GPCRs). Canonically, the histamine H-2-receptor (H2R) couples to G(s)-proteins and activates adenylyl cyclases (ACs) with subsequent adenosine-3',5'-cyclic monophosphate (cAMP) generation. Recently, the classic two-state model describing GPCR activation has been extended to a multiple-state model implying that any ligand stabilizes a ligand-specific receptor conformation, also referred to as functional selectivity. In our present study we pharmacologically characterized the H2R in human monocytes. We found dissociations in the effects of histamine (HA) and H2R agonists on cAMP accumulation and inhibition of formyl peptide-induced production of reactive oxygen species (ROS). In addition, we excluded participation of protein kinase A (PKA) in HA-induced ROS inhibition. Comparison of the potencies and efficacies of H2R agonists in monocytes, neutrophils and eosinophils unmasked cell type-specific pharmacological profiles of individual ligands. Taken together, our data extend the concept of functional selectivity to the H2R in human monocytes and demonstrate striking cell-type specificity in the pharmacological profile of the H2R. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Histamine regulates murine primary dendritic cell functions

Heiko Schenk, Detlef Neumann, Christina Kloth

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)

Article Pharmacology & Pharmacy

Lack of Histamine H4-Receptor Expression Aggravates TNBS-Induced Acute Colitis Symptoms in Mice

Eva J. Wunschel, Bastian Schirmer, Roland Seifert, Detlef Neumann

FRONTIERS IN PHARMACOLOGY (2017)

Article Pharmacology & Pharmacy

Mouse Colonic Epithelial Cells Functionally Express the Histamine H4 Receptor

Bastian Schirmer, Luisa Lindemann, Kaya Saskia Bittkau, Rukijat Isaev, Daniela Boesche, Malte Juchem, Roland Seifert, Detlef Neumann

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Article Geriatrics & Gerontology

Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice

Domiziana Costamagna, Robin Duelen, Fabio Penna, Detlef Neumann, Paola Costelli, Maurilio Sampaolesi

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)

Article Oncology

Genetic Deficiency of the Histamine H4-Receptor Reduces Experimental Colorectal Carcinogenesis in Mice

Bastian Schirmer, Tamina Rother, Inga Bruesch, Andre Bleich, Christopher Werlein, Danny Jonigk, Roland Seifert, Detlef Neumann

CANCERS (2020)

Review Biochemistry & Molecular Biology

The Function of the Histamine H4 Receptor in Inflammatory and Inflammation-Associated Diseases of the Gut

Bastian Schirmer, Detlef Neumann

Summary: Histamine is a versatile mediator involved in various physiological processes, including the regulation of inflammation. Approved compounds targeting histamine receptors are used for allergic inflammation, gastric acid reduction, and narcolepsy treatment. H4R ligands are still under investigation for inflammatory diseases, showing moderate effects so far.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Editorial Material Pharmacology & Pharmacy

Probiotics in Naunyn-Schmiedeberg's Archives of Pharmacology

Detlef Neumann, Roland Seifert

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

Histamine H1- and H4-receptor expression in human colon-derived cell lines

Jasper Carsten Schrammel, Martin Koenig, Miriam Frommer, Kaya Saskia Andersen, Marla Kirsten, Roland Seifert, Detlef Neumann, Bastian Schirmer

Summary: By studying cell lines, it was found that colon epithelial cells have functional expression of H4 receptors, which further confirmed the involvement of H4 receptors in inflammatory bowel disease and associated colon cancer. However, the transferability of these data to humans is uncertain. The expression of histamine receptor subtypes varied among different cell lines, and genetic modification is necessary for detailed functional analysis in human colon-derived cell lines.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2023)

Meeting Abstract Cell Biology

LACK OF HISTAMINE H4-RECEPTOR EXPRESSION PROTECTS MICE FROM CHEMICALLY INDUCED INFLAMMATION ASSOCIATED WITH COLON CARCINOMA

T. Rother, B. Schirmer, R. Seifert, D. Neumann

INFLAMMATION RESEARCH (2019)

Meeting Abstract Pharmacology & Pharmacy

Evidence for the involvement of histamine H4-receptor function in the pathogenesis of experimental inflammation-associated colorectal carcinoma

T. Rother, B. Schirmer, R. Seifert, D. Neumann

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2019)

Meeting Abstract Pharmacology & Pharmacy

Is the histamine H4-receptor a useful pharmacologic target in colitis?

D. Neumann, E. Wunschel, B. Schirmer

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2017)

Meeting Abstract Pharmacology & Pharmacy

No evidence for a role of the histamine H4-receptor in chronic DSS induced colitis

B. Schirmer, T. Rezniczek, R. Seifert, D. Neumann

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2016)

Meeting Abstract Pharmacology & Pharmacy

The histamine H-4-receptor affects experimental colitis due to its functional expression on epithelial cells of the mouse colon

K. Bittkau, L. Bringmann, D. Boesche, R. Isaev, B. Schirmer, R. Seifert, D. Neumann

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2018)

Article Pharmacology & Pharmacy

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib

Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci

Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Cardiac human bitter taste receptors contain naturally occurring variants that alter function

Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas

Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li

Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.

BIOCHEMICAL PHARMACOLOGY (2024)

Review Pharmacology & Pharmacy

Ferroptosis resistance in cancer: recent advances and future perspectives

Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang

Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.

BIOCHEMICAL PHARMACOLOGY (2024)